Mike is an experienced medicinal chemist who was recently a customer of Inductive Bio — a testament to his belief in the strength of the platform. He has nearly three decades of experience across big pharma and biotech, contributing from bench research to project leadership on multiple development candidates in diabetes, immunology, and oncology. Before joining, Mike was Senior Director at Delphia Therapeutics, where the team integrated traditional medicinal chemistry with predictive ADME models to explore activation lethality. His career spans Bayer Pharmaceuticals, where he delivered a clinical asset for VEGFR; Boehringer Ingelheim, where his most advanced program targeted BTK for Lupus; Blueprint Medicines, working on a Roche immuno-oncology collaboration; and Ikena Oncology, where he developed a MEK/RAF clinical asset as a molecular glue. Mike completed his graduate studies at the University of Calgary.